🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Registration is now open for the 7th International Lung Cancer Summit #ILCS25! Connect with our hosts, Alfredo Addeo MD & Solange Peters, and leading experts to get the latest developments in thoracic oncology 🫁 🗓️ 26 September from 9:30AM CEST ⬇️ Secure your seat early

Top 10 #LungCancer Oncologists for June 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Stephen V Liu, MD | Hidehito HORINOUCHI |

Published nature : Air pollution may drive TP53 and other mutations in lung cancer among never-smokers. EGFR was common in East Asia, KRAS in the West; secondhand smoke showed minimal genomic impact, and herbal toxin–linked signatures were seen in Taiwan.

Just in time for the new academic year - 50 years of progress in NSCLC in this review article JTO & JTO CRR led by Jarushka Naidoo & the IASLC communications committee. Proud to be part of this effort summarizing profound advances in this lethal disease. jto.org/article/S1556-…

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study - Journal of Thoracic Oncology #LCSM SmallCellSMASHERS jto.org/article/S1556-…

.AnnabelleGurwitch highlights the financial burden US patients face accessing targeted therapies, which are often driven by pharmacy benefit practices. 🔗 Full article in #ILCN: bit.ly/4ltwTlK #LCSM #PatientAdvocacy #IASLC

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…

Inspired by her daughter, Roxana Dronca, M.D., helped create a program that brings life-saving cancer treatment directly to patients’ homes. mayocl.in/46vfxRb

Top #LungCancer Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Stephen V Liu, MD | Aakash Desai, MD, MPH, FASCO |

Consensus statement from IASLC on molecular tumor boards in lung cancer (& oncology in general). Provides framework for implementation, report standardization, case selection, quality assessment. Performance metric: changes in management based on MTB. jto.org/article/S1556-…

Dr. Roxana Dronca, a medical oncologist, colleague, and longtime friend, has created a lasting legacy for her daughter Maya through her visionary cancer care work at Mayo and through the Maya Dronca Foundation. Read more: mayocl.in/3IebhM6

Treatment Algorithm series: Early stage NSCLC w/ Deepa Rangachari, MD, FASCO ✅ Resectable disease ✅ Role of NGS early on ✅ Stage III unresectable disease Full discussion: ⭐️ oncbrothers.com/nsclc-limited-… ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

📚 Hem/Onc boards are around the corner! Check out my interview on ASCO Connection where I share tips, strategies, and insights from my own board prep journey. Hope it helps those getting ready! connection.asco.org/do/prepared-me… #MedTwitter #OncTwitter #HemOnc #BoardExams #Fellowship

A practical guide on managing toxicities from lorlatinib chronically now Lung Cancer Journal, developed collaboratively by patients with #ALK NSCLC ALK Positive. lungcancerjournal.info/article/S0169-…

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…